Genetic discovery from the multitude of phenotypes extractable from routine healthcare data can transform understanding of the human phenome and accelerate progress toward precision medicine. However, a critical question when analyzing high-dimensional and heterogeneous data is how best to interrogate increasingly specific subphenotypes while retaining statistical power to detect genetic associations. Here we develop and employ a new Bayesian analysis framework that exploits the hierarchical structure of diagnosis classifications to analyze genetic variants against UK Biobank disease phenotypes derived from self-reporting and hospital episode statistics. Our method displays a more than 20% increase in power to detect genetic effects over other approaches and identifies new associations between classical human leukocyte antigen (HLA) alleles and common immunemediated diseases (IMDs). By applying the approach to genetic risk scores (GRSs), we show the extent of genetic sharing among IMDs and expose differences in disease perception or diagnosis with potential clinical implications.
UK Biobank 6, 7 , which has prospectively collected extensive healthrelevant phenotypic and genotypic information from 500,000 participants, allow for simultaneous investigation of multiple traits and are set to lead to a step change in the rate of genetic discovery 8,9 . However, capitalizing on the availability of population-based cohorts for biomedical research is complicated by the scale and nature of the data: the phenotypic space is multidimensional and heterogeneous, as data can be subject to observational predilections, non-uniform recording practices and longitudinal biases while phenotype prevalence is variable [10] [11] [12] [13] [14] [15] [16] . This creates new challenges that are not addressed by existing analytical methods for GWAS and phenome-wide association studies (PheWAS) . An open question is how to interrogate the many precise phenotypes obtainable from routine healthcare data at a resolution that identifies associations above and beyond those identified through GWAS, but without sacrificing statistical power. Making use of disease classification hierarchies, such as the tree of International Classification of Diseases, Tenth Revision (ICD-10) codes, provides a tractable solution. Here we have developed a new Bayesian analysis framework for identifying genetic associations across the entire health phenotype space by taking advantage of the relative topology of nodes within two tree-structured phenotypic data sets from the UK Biobank-the self-reported (SR) diagnoses that are organized using the UK Biobank classification tree, which includes 531 diagnostic terms, and the hospitalization episode statistics (HES) data that utilize ICD-10 codes and contain 16,310 diagnostic terms.
RESULTS

Tree analysis approach
To test the association of genetic variation with any given UK Biobank clinical phenotype, we want to construct a statistical framework that meets a set of fundamental requirements. First, the method must accommodate different types of genetic variation, such as (i) SNPs, (ii) haplotypes in a highly polymorphic region like the HLA gene region, or (iii) GRSs constructed using multiple SNPs or haplotypes known to be associated with a quantitative trait or complex disease. Second, for single-locus variation, any genetic model (for example, additive, dominant or full) must be accommodated. Third, the method must allow for joint analysis and quantification of evidence for association at each clinical phenotype and must estimate the genetic coefficients of effects. Next, the method must allow identification of independent genetic effects through conditional analysis. Lastly, the method must model the correlation structure of genetic effects across a n a ly s i s observed clinical phenotypes using a priori knowledge of phenotype relationships obtained from a diagnosis classification tree.
To meet these requirements, we have developed a new Bayesian analysis framework, termed TreeWAS, which models genetic coefficients across all phenotypes as a set of random variables. To model the correlation structure, we allow coefficients to evolve down a tree in a Markov process ( Fig. 1) . A known classification hierarchy determines the tree structure, where each node is a clinical term in the classification, and observations can be made at terminal and internal nodes. The prior θ determines the expected correlation between genetic coefficients across phenotypes. The coefficient at a parent node can be inherited by a child node with probability e −θ or can transition to a new uncorrelated value, with probability 1 -e −θ . This new value will be zero with a probability of 1 -π 1 or nonzero with a probability of π 1 . Thus, parameters θ and π 1 define transition probabilities controlling the Markov process. Given the model structure and the Markov process assumption, we can calculate the likelihood over genetic coefficients across all clinical phenotypes using dynamic programming (details are provided in the Supplementary Note), and we estimate a Bayes factor statistic (BF tree ) for the evidence that genetic coefficients are nonzero for at least one node. Similarly, because of the model's properties, using dynamic programming and the forwardand-backward algorithms, we can determine the marginal posterior probability (PP) at each node that the genetic coefficient is nonzero and the magnitude of this effect using the maximum a posteriori (MAP) estimator (Supplementary Note).
HLA-B*27:05 TreeWAS and PheWAS comparison
We illustrate the advantages of the TreeWAS approach as compared to existing PheWAS tests by analyzing the association of the HLA-B*27:05 allele against the UK Biobank HES data set. The HLA-B*27:05 association with ankylosing spondylitis is one of the strongest genetic effects observed in human complex diseases 17 , with an odds ratio of 46, and this allele also confers risk for reactive arthritis 18 , psoriatic arthritis 19 and anterior uveitis (iridocyclitis/iritis) 20 . Using PheWAS, where evidence of genetic association for each clinical term is estimated independently, HLA-B*27:05 was significantly associated with six ICD-10 terms after correcting for multiple testing (adjusted P (P adj ) < 0.05, using the Benjamini-Hochberg procedure 21 ), including M45 ankylosing spondylitis and M45.X9 ankylosing spondylitis (site unspecified) ( Fig. 2a ). However, this approach failed to identify associations with terms with greater granularity of clinical description and relatively low prevalence, such as M45.X6 ankylosing spondylitis with lumbar spine involvement (P = 0.01, P adj = 1.0), which is 17 times less prevalent than M45.X9 (0.08%). By contrast, when employing TreeWAS with priors θ = 1/3 and π 1 = 0.001, we observed HLA-B*27:05 associations with 145 ICD-10 terms (PP ≥ 0.75, the level of significance used throughout the analysis), which clustered in different branches of the classification tree ( Fig. 2b-e and Supplementary  Table 1 ). These prior values were chosen to maximize power and sensitivity after exploring the variability of the BF tree statistic and the number of nonzero nodes at a threshold of PP = 0.75 over the parameter space of θ and π 1 (Supplementary Fig. 1 ). As for PheWAS, there was a significant association with M45 ankylosing spondylitis (PP = 1), but TreeWAS additionally identified associations with four M45 subcategories (M45.X0, M45.X2, M45.X6 and M45.X9) rather than two (M45.X0 and M45.X9) ( Fig. 2a,b) . Moreover, there was an association with the broader spondylopathies category (M45-M49; PP = 1.0), which was likely driven by associations with M45 (PP = 1.0) and M49 (PP = 0.43), but not M47 spondylosis (PP = 0.07), despite the latter being ten times more prevalent than M45 (Fig. 2b) .
As spondylosis occurs as a result of age-related disk degeneration 22 , lack of an HLA-B*27:05 association with M47 is consistent with its non-immunological etiology.
Associations with reactive arthritis (for example, M02.39 Reiter's disease, PP = 0.78) and anterior uveitis (H20.9 iridocyclitis, unspecified, PP = 0.98) were also observed ( Fig. 2c,d) , and we detected a previously unreported HLA-B*27:05 association with H40 glaucoma (PP = 0.84) ( Fig. 2d) . As glaucoma is a common complication of chronic uveitis 23 , comorbidity may explain this association. Lastly, we observed a weak effect on L40.5 arthropathic psoriasis susceptibility (PP = 0.60), but not non-arthropathic psoriasis (PP ≤ 0.25 for L40 child nodes except L40.5), consistent with previous studies 24 ( Fig. 2e) . Therefore, our TreeWAS analysis of HLA-B*27:05 in the HES data set recapitulates known associations and demonstrates that our method can identify additional genuine associations in comparison to PheWAS.
Sensitivity and specificity analysis of TreeWAS approach using simulated data
Given the capacity of TreeWAS to identify multiple associations with HLA-B*27:05, we wanted to further investigate the method's sensitivity and specificity. To assess the relative power of TreeWAS, and to explore its robustness and accuracy, we performed two sets of simulations. In the first set, we assessed power by simulating data from a simple scenario where genetic coefficients are nonzero for a set of five clinical annotations in the tree. These annotations were chosen to occur within a single branch of the tree (clustered nodes) or across distant branches (distributed nodes). We compared the power obtained under these two scenarios when considering a range of allele frequencies. We fitted the TreeWAS model under a two-parameter setting with default parameters θ = 1/3 and π 1 = 0.001. For the alternative PheWAS model, we assumed complete independence across annotations, equivalent to setting θ → . Under the simulations with clustered nodes, the relative gain in power for identifying active nodes, where genetic coefficients are nonzero, of TreeWAS as compared to PheWAS was 20-25% across the allele frequencies tested (Fig. 3a) . This gain in power was not associated with an increased false-positive rate Figure 1 Schematic of a diagnosis classification tree and genetic coefficient transition scenarios tested. Each node in the tree represents a clinical diagnosis, and nodes are ordered in a hierarchical structure on the basis of a classification criterion (such as similarities in clinical manifestations). White nodes represent the null state where there is no genetic association with the clinical phenotype. Green, red and blue nodes represent the alternative state where there is a genetic association with the clinical phenotype, with the different colors corresponding to different, uncorrelated genetic coefficients of association. A genetic coefficient can transition from the null state to a nonzero coefficient, as in the I→B and A→2 pairs. From the nonzero state, a genetic coefficient can remain in a correlated nonzero state (as in the B→3, 3→a, 3→b and 5→e pairs); it can transition back to the null state (as in the B→4 and 5→f pairs); or it can transition to a new, uncorrelated nonzero state (as in the B→5 pair). An in-depth description of the method is provided in the supplementary note. a n a ly s i s (<0.001), as observed in nodes simulated with genetic coefficients of zero ( Fig. 3a) . When we simulated nonzero genetic coefficients in distributed nodes, there was a 1-3% reduction in power to identify active nodes for TreeWAS as compared to PheWAS (Supplementary Fig. 2) . We also observed an increase in power in quantifying the overall evidence for association with clustered nodes (3.4-5.4%), but a small decrease with distributed nodes (0.2-1.0%) ( Supplementary Figs. 3  and 4) . Therefore, when genetic coefficient correlation is captured by the classification tree, the gain in power with TreeWAS relative to PheWAS is substantial; if correlation is not well represented by the tree, then the cost incurred with the former method is minimal.
In the second simulation set, we assessed the impact of non-independence among annotations arising from the clinical data collection approach. For example, recording of a specific disease subtype for an individual may mean that other subtypes are less likely to be recorded for the same patient. We performed simulations under the null model of no genetic association using individual-level phenotype data from both UK Biobank phenotype data sets. For each simulation, we permuted the observed genotypes of HLA-B*27:05, representative of a common genetic variant (given its 4.05% allele frequency in the UK Biobank), while maintaining non-independence among annotations in the tree. For comparison, we also performed permutations of individual-level phenotype data in addition to the genetic data where all correlation was removed. With these permutations, we quantified the rate of false positives in our approach. When we permuted genotypes only, we observed an inflation of the BF tree statistic and the node-level posterior probability with the HES data set, consistent with the more prominent correlation structure in the ICD-10 tree as compared to the SR diagnosis tree (Fig. 3b,c) . Through these simulations, we estimated a false-positive rate of 0.05 and 0.01 with a log 10 (BF tree ) threshold of 10 and 20, respectively, in the HES data set, when substantial non-independence exists among nodes. For the SR data set, the false-positive rate at these thresholds was below 0.01. Thus, although non-independence among nodes can artificially increase test statistics, this can be countered by using conservative significance thresholds to maintain the false-positive rate at an appropriate level.
Effects of HLA allelic variation in the phenome
HLA region genetic variation is associated with numerous human disorders, in particular autoimmune and autoinflammatory diseases. Hence, we sought to interrogate HLA effects on the full range of SR and HES phenotypes using TreeWAS. Through conditional analysis (Online Methods and Supplementary Note), we identified independent associations for ten HLA alleles in the SR data (log 10 (BF tree ) ≥ 10) Table 1 . a n a ly s i s and eight HLA alleles in the HES data (log 10 (BF tree ) ≥ 20) ( Fig. 4 and Supplementary Tables 2 and 3) . Seven of these alleles or alleles in high linkage disequilibrium (LD; r > 0.98) were associated in both data sets ( Supplementary Fig. 5) .
These associations were fine-mapped, and the majority of the strongest effects were with IMDs, as reported previously through GWAS 17, [25] [26] [27] [28] [29] [30] (Fig. 4) . For class I alleles, we observed associations with psoriasis (HLA-C*06:02) and ankylosing spondylitis (HLA-B*27:05), and the genetic coefficients for the latter were the largest observed in the SR and HES data sets (Fig. 4a,c) . For class II alleles, HLA-DRB1*03:01 and HLA-DQB1*02:02 were observed to be independently associated with celiac disease in both data sets; these alleles tag two of the strongest known celiac disease HLA risk haplotypes, DR3-DQ2 and DR7-DQ2 (ref. 26) . In both data sets, HLA-DQA1*03:01 was identified and fine-mapped to rheumatoid arthritis; this allele is in moderate LD with HLA-DRB1*04:01 (r = 0.71), which is the likely causal allele driving this association 27 . Similarly, HLA-DQA1*03:01 was associated with type 1 diabetes (T1D), and we note that this allele is in LD with HLA-DQB1*03:02 (r = 0.67), which has been indicated as the most significantly associated T1D class II allele 26 . In the SR data set, we identified an HLA-DRB1*15:01 association and fine-mapped it to multiple sclerosis (Fig. 4a ). In the HES data set, HLA-DQB1*06:02 was identified instead and also fine-mapped to multiple sclerosis (PP = 1; Fig. 4c ), but this allele is in strong LD with HLA-DRB1*15:01 (r = 0.97) ( Supplementary Fig. 5 ). Lastly, HLA-DRB1*01:03 was finemapped to ulcerative colitis and Crohn's disease in both data sets, and it is the likely causal allele for these two types of inflammatory bowel disease (IBD) 30 .
Apart from established HLA associations with common IMDs, we also confirmed HLA effects for conditions where GWAS have not been performed, detected associations with clinical annotations linked to disease complications and identified new HLA associations with other IMDs. For example, in the SR data set, we confirmed the association of HLA-DRB1*04:04 with polymyalgia rheumatica and giant cell arteritis, which has previously been identified only through small candidate gene studies 31, 32 (Fig. 4a) . The ulcerative colitis-and Crohn's disease-associated HLA-DRB1*01:03 allele was found also to be associated with surgical procedures linked to complications of IBD, such as Z93.3 colostomy status (PP = 1) and Z93.2 ileostomy status (PP = 1), consistent with findings by the International IBD Genetics Consortium 33 (Fig. 4c) . Of the ten HLA alleles independently associated with clinical phenotypes in the SR data set, five were associated with hypothyroidism/myxoedema, and three of the eight alleles from the HES data were associated with the E03 hypothyroidism code. This disease is thus the phenotype with the largest number of independent HLA associations across both UK Biobank data sets. Associations have been reported with hypothyroidism for both HLA class I and class II loci, but the specific alleles driving these associations are not well resolved 34, 35 , apart from a recently reported HLA-DQA1*05:01-HLA-DQB1*02:01-HLA-DRB1*03:01 (DR3-DQ2 haplotype) association 36 . In addition to HLA-DRB1*03:01, we refined the HLA associations with hypothyroidism to two further independent risk alleles, HLA-DQA1*03:01 and HLA-DRB1*01:03, and two independent protective alleles, HLA-B*15:01 and HLA-DPB1*01:01 ( Fig. 4 and Supplementary Table 4 ). Our HLA analysis therefore demonstrates the validity of our method as it can identify known genetic associations and can facilitate discovery of new associations for relatively understudied diagnoses.
Genetic risk score associations with IMDs
Outside of the HLA region, over the last decade, understanding of genetic susceptibility to the common IMDs has increased tremendously, with tens to hundreds of risk loci being identified for each disease 37 . However, given the prevalence of IMDs in the UK Biobank and the typically small effect sizes estimated, we expect low power at individual loci. For example, when considering nine of the most common autoimmune and autoinflammatory diseases (Online Methods), we observed evidence of association (log 10 a n a ly s i s SNPs (12.96% of GWAS SNPs tested) in the SR data set and 125 individual SNPs (25.30%) in the HES data set. Nevertheless, we can gain power by combining the effects of multiple typed and imputed susceptibility variants in a GRS (Online Methods) and using the TreeWAS approach to assess the relationship of the GRS with the UK Biobank phenome (Fig. 5) .
Typically, GRSs best identified those clinical annotations from which they were constructed, with secondary associations detected for conditions with shared genetic risk. For example, Crohn's disease and ulcerative colitis have high genetic correlation 38 , although disease-specific susceptibility loci have been identified for each and heterogeneity in effect sizes has been observed 39 . The GRS for Crohn's disease was thus associated with both Crohn's disease itself as well as ulcerative colitis, but the magnitude of the genetic coefficients was greater for Crohn's disease, as expected (β = 0.86 versus β = 0.44 in SR data and β = 0.73 versus β = 0.35 in HES data for Crohn's disease and ulcerative colitis, respectively). However, the GRS for ulcerative colitis could not differentiate these two clinical annotations, with estimated genetic coefficients of the same magnitude for both Crohn's disease and ulcerative colitis (β = 0.68 in SR data and β = 0.64 in HES data; Fig. 5a,b) . This indicates some level of variation in the precision of different GRSs in identifying specific phenotypes, such that the discriminatory capacity of GRSs will depend on the degree of genetic sharing among conditions and may require consideration of additional clinical features 33 .
For all associations, genetic coefficients were less than 1, demonstrating a degree of dilution in phenotype detection across both the SR and HES data sets; we note that simulation analyses estimated an Table 9 ). (c) The tree depicts the hierarchical structure of HES-derived clinical phenotypes as determined by ICD-10 classification (showing nodes with PP > 0.75 and their parent nodes). The graph shows estimated effect sizes for the heterozygous genotype of the different HLA alleles on susceptibility to each clinical phenotype. (d) Evidence of association for each HLA allele with at least one node in the tree in the conditional TreeWAS analysis using the HES data (supplementary Table 10 ). Estimates for heterozygous and homozygous genotype effect sizes and descriptions of all phenotypes shown are available in supplementary Tables 2 and 3 . AS, ankylosing spondylitis; CD, Crohn's disease; CI, confidence interval; COE, celiac disease; ENT, ear, nose, throat; MAP, maximum a posteriori; MS, multiple sclerosis; PS, psoriasis; RA, rheumatoid arthritis; T1D, type 1 diabetes; UC, ulcerative colitis. a n a ly s i s expected dilution of ~15% due to winner's curse ( Supplementary  Table 5 and Supplementary Note). The least dilution was observed for association of the celiac disease GRS with this disease (β = 0.96 and β = 0.87 in the SR and HES data sets, respectively). The celiac disease phenotypes derived from the UK Biobank healthcare data are thus highly comparable to the clinically ascertained disease phenotype used in the GWAS 40 from which the variants for the celiac disease GRS were obtained. Across both data sets, the greatest dilution of the association between a GRS and its respective disease was observed for rheumatoid arthritis (β = 0.43 and β = 0.55 in the SR and HES data sets, respectively), while, in HES data specifically, the ankylosing spondylitis GRS was not associated with the disease (PP = 0.01), potentially owing to the small number of patients with ankylosing spondylitis in this data set (n = 146), and in SR data the SLE GRS association with SLE had a genetic coefficient of only 0.20 (Fig. 5a,b) .
Overall, the GRS associations were largely consistent between the SR and HES data sets, and, for GRSs and their respective diseases, the estimated genetic coefficients were weakly positively correlated (r corrected = 0.23, correcting for measurement error) (Fig. 5c) . Strikingly, although the capacity of the SLE GRS to identify SLE itself in SR data was so diluted that the SLE GRS was in fact a better predictor of celiac disease (β = 0.57) ( Fig. 5a) , in the HES data set this was not the case. The SLE GRS was most predictive of M32.9 SLE (β = 0.50, PP = 1.00) and, to a lesser extent, K90.0 celiac disease (β = 0.47, PP = 1.00) (Fig. 5b) . This discrepancy between the SR and HES data sets suggests differences in the diseases annotated as SLE in the two data sets, which may in turn reflect differences in disease perception or diagnosis that could have clinical implications. Notably, in the SR data, SLE was also associated with the celiac disease GRS (β = 0.13), but this was not the case in the HES data, further supporting a distinction between SLE phenotypes in the two data sets.
Secondary associations of the GRSs were identified either with known complications of the disease with which the primary association was observed or with other IMDs. For example, as for the a n a ly s i s HLA-DRB1*01:03 associations, the ulcerative colitis GRS was associated with colostomy and ileostomy events (β = 0.31, PP = 0.98 and β = 0.31, PP = 1, respectively), as was the Crohn's disease GRS, although the effect size magnitude was lower (β = 0.03, PP = 0.91 and β = 0.03, PP = 0.87, respectively). Also paralleling the HLA analysis, hypothyroidism was associated with several GRSs: five and four of the nine GRSs tested were associated with the disease in the SR and HES data sets, respectively, with those for celiac disease, rheumatoid arthritis, SLE and T1D being found in both data sets. Hence, hypothyroidism is the single phenotype with the largest number of different GRS associations (Fig. 5a,b and Supplementary Tables 6 and 7) .
DISCUSSION
By exploiting the inherent hierarchical structure of diagnostic classifications, our Bayesian analysis framework addresses a fundamental challenge for the analysis of high-dimensional, heterogeneous routine healthcare data: how to identify statistically significant genetic associations when interrogating thousands of diagnoses without employing methods 11, 13 that sacrifice phenotypic resolution. When applying TreeWAS to interrogate the effect of the HLA region on the UK Biobank phenome, associations were identified with 143 and 966 nodes in the SR and HES data sets, respectively. Assessing the impact of IMD GRSs also identified associations with 151 and 810 nodes in the two respective data sets. The total number of nodes identified demonstrates the power of TreeWAS for detecting associations in data sets where numerous weak but correlated effects are present across the classification tree. Among the many active nodes for which genetic associations were observed, previously established effects of HLA alleles on specific IMDs were detectable, as were effects for relatively understudied conditions. Notably, multiple new associations with HLA alleles were discovered for hypothyroidism. Although not all previously reported HLA associations could be detected for any single IMD (such as ankylosing spondylitis 41 or multiple sclerosis 29 ) owing to limited power with the current UK Biobank data sets, the capacity for genetic discovery will improve with increasing cohort size, and associations with nodes displaying substantial granularity of clinical description were already identifiable.
In the GRS analysis, associations between GWAS-derived GRSs and their respective diseases were typically the strongest effects observed, even without HLA allele inclusion, demonstrating that non-HLA variants can provide precision for detecting specific IMDs. Cross-disease associations of GRSs were also identified, particularly for hypothyroidism, and this previously unappreciated extent of genetic sharing indicates a common, genetically determined pathogenesis. For all GRS associations, dilution of the capacity for phenotype detection was observed but was largely comparable between the SR and HES data sets. An intriguing exception was the differential association of the SLE GRS with the respective SLE terms in the two data sets: this GRS could not precisely predict the self-reported disease but could accurately detect the hospitalization-record-derived phenotype. In comparison to the other IMDs investigated, SLE is a more heterogeneous, systemic condition, which consequently presents a substantial diagnostic challenge 42 . Therefore, this discrepancy in the magnitude of SLE GRS association could reflect incorrect reporting of the disease, disease overdiagnosis not discernible in the HES data if hospitalization is associated with more clear-cut diagnosis, or greater disease heterogeneity whereby SLE as defined in GWAS and in the HES data represents only a subset of a more genetically variable syndrome.
Identifying misclassification, misdiagnosis and miscoding in routine healthcare data is an ongoing challenge, although there are recognized instances, such as inaccuracy in T1D and type 2 diabetes (T2D) differentiation 43 . In the UK Biobank, the T1D GRS is not associated with T2D terms in the SR data (PP = 0.0002) and shows weak evidence of association in the HES data (PP = 0.52). However, the T2D GRS, which can accurately detect T2D terms (β = 0.80, PP = 1.00 and β = 0.71, PP = 1.00 in the SR and HES data sets, respectively), is also associated with T1D in the HES data (β = 0.71, PP = 1.00) but not the SR data (PP = 0.30; Supplementary Table 8 and Supplementary Note). These cross-disease associations may be attributable to T1D/ T2D misclassification, misdiagnosis and miscoding 43 (Supplementary  Figs. 6 and 7, and Supplementary Note) but also to genetic sharing 44 and poor distinction of patients with latent autoimmune diabetes of adulthood 45 , whose genetic profiles comprise a mixture of T1D and T2D risk loci 46 . Thus, the SLE and diabetes examples demonstrate how exploring the genetic basis of the healthcare phenome can expose disease areas where improvements are required to ameliorate disease perception or strengthen diagnostic practices. Digital phenotyping using genetic data in combination with longitudinal clinical information, physical measures and biomarkers 43, 47 could help to rectify misclassification, misdiagnosis and miscoding present in healthcare data and to infer missing phenotypes. This could in turn facilitate patient management, particularly if it enables correction of treatment strategies within an actionable time frame.
Integration of genomic data with routine healthcare information offers much potential to learn about differences in disease risk, diagnosis and reporting within and between healthcare systems, including between countries. Moreover, increased incorporation of correlated, high-dimensional phenotypes (for example, from molecular, cytometry and imaging readouts), including measures of temporal disease progression 48 , may lead to a genetically driven understanding of the architecture of the human phenome and of causal relationships. The value of TreeWAS lies in enhancing power to identify groups of endpoints affected by specific genetic risk factors, by exploiting the encoding of medical ontologies. A corollary is that structures that better capture the underlying biological process affecting the origin and progression of disease should be better correlated with genetic risk factors. Although generalizing the TreeWAS method to structures reflecting temporal progression and associated quantitative data modalities requires future development, we believe that it is an important step toward the goal of learning a genetically motivated classification of disease and associated phenotypes.
URLs. UK Biobank, http://www.ukbiobank.ac.uk/; UK Biobank genotyping procedure and genotype calling protocols, http://biobank. ctsu.ox.ac.uk/crystal/refer.cgi?id=155580; UK Biobank internal quality control procedures, http://biobank.ctsu.ox.ac.uk/crystal/refer. cgi?id=155580; HLA*IMP, https://oxfordhla.well.ox.ac.uk/hla/; World Health Organization ICD-10 disease classification codes, http://www.who.int/classifications/icd/en/.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
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